Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Impact of Prevnar 13 on Ear Infections in Children

Completed

Conditions: Mastoiditis
Acute Otitis Media

Interventions: Other: No intervention

First Posted Date: 2011-01-10

Last Posted Date: 2023-05-23

Lead Sponsor: Pfizer

Target Recruit Count: 391

Registration Number: NCT01272999

Locations: 🇺🇸
Brenner Children's Hospital - Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
🇺🇸
Children's Memorial Hospital- Feinberg School Medicine, Northwestern University, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Los Angeles - University of Southern California School of Medicine, Los Angeles, California, United States

and more 5 locations

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: NIDDM
Diabetes Mellitus, Type 2

Interventions: Drug: PF-04937319
Drug: Placebo

First Posted Date: 2011-01-10

Last Posted Date: 2017-02-01

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT01272804

Locations: 🇺🇸
MRA Clinical Research, South Miami, Florida, United States
🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

and more 1 locations

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment F
Drug: Treatment C
Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment G
Drug: Treatment E

First Posted Date: 2011-01-07

Last Posted Date: 2018-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01272375

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

Phase 3

Completed

Conditions: Onychomycosis of Toenails

Interventions: Drug: AN2690 Topical Solution, 5%
Drug: Solution Vehicle

First Posted Date: 2011-01-06

Last Posted Date: 2019-02-22

Lead Sponsor: Pfizer

Target Recruit Count: 594

Registration Number: NCT01270971

Locations: 🇺🇸
Investigational Site, Spokane, Washington, United States

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Completed

Conditions: Parkinson's Disease
Hyperprolactinemia

Interventions: Drug: Study Drug

First Posted Date: 2011-01-05

Last Posted Date: 2014-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 22014

Registration Number: NCT01270711

A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form

Phase 1

Completed

Conditions: Biological Availability

Interventions: Drug: methylprednisolone

First Posted Date: 2010-12-28

Last Posted Date: 2012-06-28

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01267201

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Multiple Dose Dental Pain Study Of Ibuprofen Extended Release

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Ibuprofen 600 mg ER
Drug: Placebo

First Posted Date: 2010-12-24

Last Posted Date: 2018-08-15

Lead Sponsor: Pfizer

Target Recruit Count: 106

Registration Number: NCT01266161

Locations: 🇺🇸
Premier Research, Austin, Texas, United States
🇺🇸
Central Texas Oral Surgery Associates, Austin, Texas, United States

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: PF-04191834

First Posted Date: 2010-12-23

Last Posted Date: 2015-10-16

Lead Sponsor: Pfizer

Registration Number: NCT01265732

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CP-690,550 (tasocitinib)

First Posted Date: 2010-12-17

Last Posted Date: 2013-01-23

Lead Sponsor: Pfizer

Target Recruit Count: 69

Registration Number: NCT01262118

Locations: 🇭🇺
Pfizer Investigational Site, Budapest, Hungary

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Phase 1

Terminated

Conditions: Cachexia

Interventions: Drug: PF-05230901

First Posted Date: 2010-12-17

Last Posted Date: 2011-10-12

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT01262690

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy